Therapeutically, PTCL subtypes presenting TET2 mutations or TET2 inhibition from other causes could be thought of as having a sensitivity to hypomethylating agents (HMAs) like azacytidine (AZA) and decitabine (DAC). The gene discussed is TET2; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.